Differential effects of P-glycoprotein and multidrug resistance protein-1 on productive human immunodeficiency virus infection

Journal of Infectious Diseases

Volumn 186, Issue 3, 2002, Pages 332-340

  Speck, R Renae ^a   Hildreth, James ^a   Flexner, Charles ^a,b,c  

^a Pharmacology and Molecular Sciences   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; VIRUS INHIBITION;

CALCIUM CHANNEL BLOCKERS; CELLS, CULTURED; DNA, VIRAL; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, VIRAL; GENISTEIN; HELA CELLS; HIV; HIV INFECTIONS; HUMANS; P-GLYCOPROTEIN; PROBENECID; TRANSFECTION; VERAPAMIL; VIRUS REPLICATION;

EID: 0036681943     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/341464     Document Type: Article

References (50)

1. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters
2. P-glycoprotein (MDR 1 gene product) in cells of the immune system: Its possible physiologic role and alteration in aging and human immunodeficiency virus-1 (HIV-1) infection
3. Symmetry and structure in P-glycoprotein and ABC transporters: What goes around comes around
4. Multidrug resistance: Molecular mechanisms and clinical relevance
5. Multidrug resistant proteins
6. P-glycoprotein and multidrug resistance
7. Merck frosst award lecture 1998. Molecular dissection of the human multidrug resistance P-glycoprotein
8. Structural, mechanistic and clinical aspects of MRP1
9. Human immunodeficiency virus 1-induced expression of P-glycoprotein
10. Resistance of HIV-1 to AZT might also involve the cellular expression of multidrug resistance P-glycoprotein
11. Induction of the multidrug-transporter P-glycoprotein by 3′-azido-3′-deoxythymidine (AZT) treatment in tumor cell lines
12. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter
13. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
14. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
15. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
16. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
17. P-glycoprotein-overexpressing multidrug-resistant cells are resistant to infection by enveloped viruses that enter via the plasma membrane
18. Effect of ABC transporters on HIV-1 infection: Inhibition of virus production by the MDR1 transporter
19. Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts
20. Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26
21. Evaluation by dot-immunoassay of the differential distribution of cell surface and intracellular proteins in glycosylphosphatidylinositol-rich plasma membrane domains
22. Mutations in the cytoplasmic domain of human immunodeficiency virus type 1 transmembrane protein impair the incorporation of Env proteins into mature virions
23. Detection of replication-competent and pseudo-typed human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene
24. Traffic, polarity, and detergent solubility of a glycosylphosphatidylinositol-anchored protein after LDL-deprivation of MDCK cells
25. Differential regulation of Src-family protein tyrosine kinases in GPI domains of T lymphocyte plasma membranes
26. Exclusion of CD45 inhibits activity of p561ck associated with glycolipid-enriched membrane domains
27. The role of multidrug resistance-associated protein (MRP) expression in multidrug resistance
28. Functional detection of MDR1/P170 and MRP/P190-mediated multidrug resistance in tumour cells by flow cytometry
29. Probenecid reverses multidrug resistance in multidrug resistance-associated protein-overexpressing HL60/AR and H69/AR cells but not in P-glycoprotein-overexpressing HL60/Tax and P388/ADR cells
30. Trans-membrane P-glycoprotein (P-gp/P-170) in HIV infection: Analysis of lymphocyte surface expression and drug-unrelated function
31. Intracellular expression of P-170 glycoprotein in peripheral blood mononuclear cell subsets from healthy donors and HIV-infected patients
32. + T cells from patients with human immunodeficiency virus type 1 infection
33. P-glycoprotein expression in acute myeloblastic leukemia analyzed by immunocytochemistry and flow cytometry
34. Effect of stavudine (d4T) and zidovudine (ZDV) on expression of the P-glycoprotein drug transporter in an HIV-1-infected patient
35. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells
36. Short communication: Expression of P-glycoprotein and multidrug resistance-associated protein in healthy volunteers and HIV- infected patients
37. Lipid rafts and HIV pathogenesis: Host membrane cholesterol is required for infection by HIV type 1
38. Membrane raft microdomains mediate lateral assemblies required for HIV-1 infection
39. Functional rafts in cell membranes
40. The packing of the transmembrane segments of human multidrug resistance P-glycoprotein is revealed by disulfide cross-linking analysis
41. Drug-stimulated ATPase activity of human P-glycoprotein requires movement between transmembrane segments 6 and 12
42. Evidence that the multidrug resistance protein (MRP) functions as a co-transporter of glutathione and natural product toxins
43. Monoclonal antibodies that inhibit the transport function of the 190-kDa multidrug resistance protein. MRP: Localization of their epitopes to the nucleotide-binding domains of the protein
44. The multidrug resistance protein family
45. Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione
46. The role of glutathione in lymphocyte activation. I. Comparison of inhibitory, effects of buthionine sulfoximine and 2-cyclohexene-1-one by nuclear size transformation
47. Suppression of human immunodeficiency virus expression in chronically infected monocytic cells by glutathione, glutathione ester, and N-acetylcysteine
48. CD4 and CD8 T cells with high intracellular glutathione levels are selectively lost as the HIV infection progresses
49. Glutathione deficiency is associated with impaired survival in HIV disease
50. Intracellular glutathione as a possible direct blocker of HIV type 1 reverse transcription